Wei Cong, Chupak Louis S, Philip Thomas, Johnson Benjamin M, Gentles Robert, Drexler Dieter M
1Pharmaceutical Candidate Optimization, Molecular Sciences & Candidate Optimization, Research and Development, Bristol-Myers Squibb, Wallingford, CT, USA.
J Biomol Screen. 2014 Feb;19(2):297-307. doi: 10.1177/1087057113492852. Epub 2013 Jun 24.
The present study describes a novel methodology for the detection of reactive compounds using in vitro peptide-trapping and liquid chromatography-high-resolution accurate mass spectrometry (LC-HRMS). Compounds that contain electrophilic groups can covalently bind to nucleophilic moieties in proteins and form adducts. Such adducts are thought to be associated with drug-mediated toxicity and therefore represent potential liabilities in drug discovery programs. In addition, reactive compounds identified in biological screening can be associated with data that can be misinterpreted if the reactive nature of the compound is not appreciated. In this work, to facilitate the triage of hits from high-throughput screening (HTS), a novel assay was developed to monitor the formation of covalent peptide adducts by compounds suspected to be chemically reactive. The assay consists of in vitro incubations of test compounds (under conditions of physiological pH) with synthetically prepared peptides presenting a variety of nucleophilic moieties such as cysteine, lysine, histidine, arginine, serine, and tyrosine. Reaction mixtures were analyzed using full-scan LC-HRMS, the data were interrogated using postacquisition data mining, and modified amino acids were identified by subsequent LC-HRMS/mass spectrometry. The study demonstrated that in vitro nucleophilic peptide trapping followed by LC-HRMS analysis is a useful approach for screening of intrinsically reactive compounds identified from HTS exercises, which are then removed from follow-up processes, thus obviating the generation of data from biochemical activity assays.
本研究描述了一种使用体外肽捕获和液相色谱-高分辨率精确质谱(LC-HRMS)检测反应性化合物的新方法。含有亲电基团的化合物可以与蛋白质中的亲核部分共价结合并形成加合物。这种加合物被认为与药物介导的毒性有关,因此在药物研发项目中代表潜在的风险。此外,在生物筛选中鉴定出的反应性化合物可能会产生一些数据,如果不了解化合物的反应性质,这些数据可能会被误解。在这项工作中,为了便于对高通量筛选(HTS)中的命中化合物进行分类,开发了一种新的检测方法,以监测疑似具有化学反应性的化合物形成共价肽加合物的情况。该检测方法包括在生理pH条件下,将测试化合物与合成制备的含有多种亲核部分(如半胱氨酸、赖氨酸、组氨酸、精氨酸、丝氨酸和酪氨酸)的肽进行体外孵育。使用全扫描LC-HRMS分析反应混合物,通过采集后的数据挖掘对数据进行查询,并通过后续的LC-HRMS/质谱鉴定修饰的氨基酸。该研究表明,体外亲核肽捕获后进行LC-HRMS分析是一种用于筛选从HTS实验中鉴定出的固有反应性化合物的有用方法,这些化合物随后从后续过程中去除,从而避免了生化活性测定数据的产生。